| Result: | Significantly reduced the disease activity index (DAI) with prolonged colon length and increased bodyweight at dose of 20 mg/kg.
Significantly ameliorated the DSS-induced colonic pathological alternations and decreased histological scores.
Markedly attenuated colonic inflammation by alleviating inflammatory cell infiltration and inhibiting myeloperoxidase (MPO) and cytokines (TNF-α, IFN-γ, IL-1β, IL-6, IL-4 and IL-10) productions in DSS mice.
Substantially upregulated the expression of tight junction proteins (zonula occludens-1, zonula occludens-2, claudin-1, occludin) and mRNA expression of mucins (mucin-1 and mucin-2), and decreased the Bax/Bcl-2 ratio. |